BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260309
DTEND;VALUE=DATE:20260311
DTSTAMP:20260515T020530
CREATED:20251016T091056Z
LAST-MODIFIED:20251016T091056Z
UID:42214-1773014400-1773187199@www.pharmajournalist.com
SUMMARY:7th Annual AI in Drug Discovery Conference
DESCRIPTION:The 7th Annual AI in Drug Discovery Conference\, hosted by SAE Media Group\, takes place \n9-10 March 2026 at Hilton London Kensington. This event explores how AI\, machine learning\, and automation are transforming drug discovery – from generative design and molecular modelling to clinical trial optimisation. \nAttendees will hear from Big Pharma and Biotech senior leaders including Novartis\, GSK\, AstraZeneca\, Sanofi\, and more\, with sessions covering LLMs\, autonomous agents\, and MLOps. With sponsors like Schrödinger\, the conference delivers cutting-edge insights\, high-level networking\, and practical strategies to accelerate innovation. \nBook now
URL:http://www.pharmajournalist.com/event/7th-annual-ai-in-drug-discovery-conference/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:alessandra.demaria@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260317
DTEND;VALUE=DATE:20260320
DTSTAMP:20260515T020530
CREATED:20251125T102350Z
LAST-MODIFIED:20251125T102350Z
UID:42483-1773705600-1773964799@www.pharmajournalist.com
SUMMARY:5th Annual Novel Conjugates Summit
DESCRIPTION:Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads and differentiated targeting formats for overcoming drug resistance\, improved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs\, as well as the exploration of non-oncology indications. \nThe 5th Novel Conjugates Summit is the industry’s only dedicated meeting for an insider view into which novel approaches are currently being explored\, what benefit each approach has and the directions the space is heading. \nAttendees gain valuable competitive insight into emerging technologies\, early data\, and the rationale behind each approach\, from established pharma leaders to the newest biotech entrants. Whether your goal is to benchmark your pipeline\, explore partnership opportunities\, or stay ahead of fast-moving design trends\, this summit offers a front-row seat to the next wave of conjugate innovation. \nView the program: https://ter.li/m5sjll
URL:http://www.pharmajournalist.com/event/5th-annual-novel-conjugates-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260323
DTEND;VALUE=DATE:20260326
DTSTAMP:20260515T020530
CREATED:20260210T171107Z
LAST-MODIFIED:20260210T171107Z
UID:42862-1774224000-1774483199@www.pharmajournalist.com
SUMMARY:11th Innate Killer Summit
DESCRIPTION:The 11th Innate Killer Summit stands at the forefront of innovation in innate immunity\, offering an unparalleled platform for exploring the next generation of NK cell-based therapies and innate immune strategies. As the biopharma industry accelerates its focus on immuno-oncology and cell therapy\, this is the only summit that brings together leading experts and decision-makers to address the scientific\, clinical\, and commercial challenges shaping the dynamic NK field. \nThis year’s faculty includes trailblazers from companies driving NK cell innovation\, such as Artiva Biotherapeutics\, Alloplex Biotherapeutics\, Glycostem\, Indapta Therapeutics\, ImmuneBridge\, and Senti Bio\, alongside academic leaders from institutions like the University of Pennsylvania and MD Anderson Cancer Center. Their insights will illuminate breakthroughs in NK cell engineering\, combination strategies\, and scalable manufacturing solutions that are crucial for advancing these therapies from the bench to the bedside. \nAttendees will gain exclusive access to discussions on optimizing NK cell persistence\, enhancing cytotoxicity\, and overcoming tumor microenvironment challenges. The program also delves into clinical trial progress\, regulatory pathways\, and investment trends\, providing a comprehensive view of how NK cell platforms are transforming cancer treatment and unlocking new therapeutic frontiers. \nThe summit provides a unique opportunity to capture the latest scientific developments\, strategic partnerships\, and commercialization strategies that are redefining the immunotherapy landscape. Expect candid conversations with industry leaders\, data-driven insights\, and forward-looking perspectives on how innate immunity is shaping the future of oncology. \nTo know more visit: https://ter.li/5fn4q8
URL:http://www.pharmajournalist.com/event/11th-innate-killer-summit/
LOCATION:The Westin San Diego Bayview\, 400 W Broadway\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260324
DTEND;VALUE=DATE:20260327
DTSTAMP:20260515T020530
CREATED:20260107T092223Z
LAST-MODIFIED:20260107T092251Z
UID:42661-1774310400-1774569599@www.pharmajournalist.com
SUMMARY:Immune Resetting: B-Cell Mediated & Beyond
DESCRIPTION:Immune Resetting: B-Cell Mediated & Beyond Summit is redefining the conversation around immune modulation and therapeutic innovation. As the global biopharma industry accelerates its focus on autoimmune and inflammatory diseases\, this summit provides an exclusive platform for uncovering the next wave of breakthroughs in B-cell biology and beyond. \nThe event brings together leading immunologists\, clinical researchers\, and pharma executives to explore how precision targeting of B-cell pathways is transforming treatment paradigms. From novel mechanisms of immune resetting to advanced biologics and cell-based strategies\, attendees will gain unparalleled insights into the science driving durable responses and improved patient outcomes. \nConnect with experts from Cabaletta Bio\, GentiBio\, Kite Pharma\, FAU\, Cullian Therapeutics\, Kali Therapeutics\, University of Pittsburgh\, Bristol Myers Squibb\, Oblenio Bio\, and more. \nBeyond the science\, the summit addresses critical challenges in translating these innovations into the clinic\, covering biomarker development\, regulatory considerations\, and scalable manufacturing solutions. With autoimmune disorders and chronic inflammation representing multi-billion-dollar markets\, the discussions will highlight how emerging therapies can meet unmet needs and unlock new commercial opportunities. \nExpect deep dives into cutting-edge research\, candid conversations on investment trends\, and strategic perspectives from industry leaders shaping the next generation of immune-modulating therapies. \nJoin the summit to discover how immune resetting is not just a scientific milestone but a transformative force in global healthcare\, positioning biopharma at the forefront of innovation and patient-centric solutions. \nSee what the current attendees are looking forward to: \n“I look forward to hearing and seeing the latest developments in immune resetting and meeting with a diverse group of researchers in this field. I am also excited to present Hinge’s GEM-DIMER molecule\, HB2198\, for depletion of CD19/CD20 expressing B cells.” \nSenior Director – Preclinical Development\, Hinge Bio  \n“I am interested to share our observations for B-cell depletion and reconstitution in Rese-cel treated individuals and hear what others have seen in their trials.” \nPrincipal Scientist\, Cabaletta Bio 
URL:http://www.pharmajournalist.com/event/immune-resetting-b-cell-mediated-beyond/
LOCATION:AKA Back Bay\, Boston\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260324
DTEND;VALUE=DATE:20260327
DTSTAMP:20260515T020530
CREATED:20260123T104451Z
LAST-MODIFIED:20260123T110056Z
UID:42781-1774310400-1774569599@www.pharmajournalist.com
SUMMARY:9th Gene Therapy Development Summit
DESCRIPTION:Gene therapy is entering a defining new chapter. After a period of challenge and recalibration\, the field is regaining momentum\, driven by resilient teams who remain committed to transforming patients’ lives. With renewed confidence\, fresh investment\, and major acquisitions signalling a return to growth\, the industry is refocusing on overcoming the critical barriers of safety\, efficacy\, scalability\, and commercial viability. \nThe 9th Gene Therapy Development Summit returns to Boston as the premier meeting point for the global gene therapy community. Bringing together 70+ senior leaders\, academic and technical experts from organisations including Bayer\, Astellas Pharmaceuticals\, REGENXBIO\, AskBio\, Ocugen\, CureDuchenne Ventures and more\, this industry-led forum provides an unrivalled opportunity to share insights\, restore confidence\, and chart a sustainable path forward for gene therapy development. \nDesigned to span the full end-to-end development pipeline\, the summit connects professionals across pre-clinical development\, manufacturing\, analytical development\, clinical operations\, and regulatory affairs. Across 3 days of cutting-edge strategic and technical sessions\, attendees will gain practical learnings on next-generation delivery technologies\, gene editing\, assay development\, and scalable manufacturing strategies\, all with a focus on optimising clinical impact and improving risk–benefit profiles. \nNetworking sits at the heart of the summit experience. With 10+ dedicated networking breaks\, a CEO & Investor Panel\, and carefully curated opportunities to meet peers\, partners\, and decision-makers\, the event is built to foster meaningful\, long-term industry connections. Whether you are looking to exchange technical insights\, explore collaboration opportunities\, or build strategic partnerships\, this is the place to connect with the people shaping the future of gene therapy. \nFeaturing 70+ world-leading speakers\, including C-level executives\, scientific innovators\, and regulatory leaders\, the summit offers a truly comprehensive and collaborative environment for learning\, discussion\, and deal-making. From early-stage development through to clinical and commercial success\, this is your definitive forum to stay ahead in an evolving gene therapy landscape. \nTo learn more about the event\, visit our website here: https://ter.li/b0hfxq
URL:http://www.pharmajournalist.com/event/9th-gene-therapy-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260406
DTEND;VALUE=DATE:20260409
DTSTAMP:20260515T020530
CREATED:20251119T144046Z
LAST-MODIFIED:20251119T144046Z
UID:42432-1775433600-1775692799@www.pharmajournalist.com
SUMMARY:5th LNP Formulation & Process Development Summit
DESCRIPTION:Returning to Boston in April 2026\, the 5th LNP Formulation & Process Development Summit is the only industry-led meeting covering end-to-end LNP development. This Summit will be providing the latest scientific content to advance your LNP development for a variety of payloads and therapeutic applications\, from mRNA vaccines to next-generation cell and gene therapies. \nThe 2026 program will dive into 3 parallel tracks\, including: Analytical Development & Characterization\, Formulation & Delivery and Process Development & Manufacturing. This is your opportunity to divide and conquer\, where you can send different members across your team amongst 250+ LNP innovators\, to ensure you gain a comprehensive understanding of the entire LNP development pipeline. From early formulation through to commercial-scale production\, you can return to your company equipped with the insights needed to accelerate your LNP-mediated medicines. \nLearn more in the official event guide here: https://ter.li/y6ipkw \nCurated in collaboration with our Scientific Advisory Board\, Annette Bak (AstraZeneca)\, Luis Brito (Beam Therapeutics)\, and Ching Kim Tye (Sanofi)\, this premier forum is designed to deliver LNP-specific networking and knowledge sharing. Our unmissable agenda highlights include: \n\nAttracting Investment & Acquisition Opportunities with Capstan Therapeutics\, GV and Chiesi Global Rare Diseases\nAchieving Extrahepatic Targeting with LNPs with Alnylam\, Servier and Novartis\nLNPs for Cell & Gene Therapy Delivery with Yoltech Therapeutics\, Innorna and Corner Therapeutics\nInteractive LNP-Focused Workshop Day with Novo Nordisk\, GSK and Editas Medicines\nGain a Refresher on LNP Core Principles with Land Therapeutics\, Beam Therapeutics and Arbor Biotechnology\nFormulating Thermostable LNPs with Eli Lilly & Co and AstraZeneca\n\nKeen to find out more? Access our event overview on the LNP website here: https://ter.li/y6ipkw
URL:http://www.pharmajournalist.com/event/5th-lnp-formulation-process-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260414
DTEND;VALUE=DATE:20260417
DTSTAMP:20260515T020530
CREATED:20251125T111346Z
LAST-MODIFIED:20251125T111346Z
UID:42493-1776124800-1776383999@www.pharmajournalist.com
SUMMARY:3rd Annual GLP-1 Based Therapeutics Summit
DESCRIPTION:Welcome to the 3rd GLP-1 Based Therapeutics Summit – the essential industry forum dedicated to solving the critical challenges of GLP-1 combinations\, mastering tolerability\, drug delivery\, and seizing the multi-billion dollar opportunity in non-obesity indications. \nDriven by unprecedented clinical success\, this revolutionary drug class has created multi-billion dollar franchises\, but the market is now reaching a critical juncture where differentiation is everything. The pressure is on to move beyond monotherapy and unlock new levels of efficacy in areas like neuroscience and cardiorenal protection\, promising unparalleled potential to conquer widespread chronic diseases. \nThe 3rd GLP-1 Based Therapeutics Summit stands as the global forum for experts dedicated to accelerating this vital progress. This year\, we’re diving deep into the game-changing potential of multi-agonist combinations\, next-generation tolerability\, and strategic commercial planning. \nHear from the titans of the pharmaceutical industry\, including Eli Lilly\, AstraZeneca\, Merck\, and Takeda\, as well as innovative biotechs and financial institutions who will share their groundbreaking research and strategies for developing best-in-class treatments that transform patient lives. \nView the full event guide: https://ter.li/p453jn
URL:http://www.pharmajournalist.com/event/3rd-annual-glp-1-based-therapeutics-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260420
DTEND;VALUE=DATE:20260422
DTSTAMP:20260515T020530
CREATED:20260106T122120Z
LAST-MODIFIED:20260114T145543Z
UID:42646-1776643200-1776815999@www.pharmajournalist.com
SUMMARY:SmartLab Exchange USA
DESCRIPTION:The SmartLab Exchange USA is an exclusive\, invitation-only event designed for senior laboratory\, R&D\, and digital transformation leaders across pharma\, biotech\, chemicals\, FMCG\, and food & beverage. This two-day forum brings together more than 60 decision-makers to tackle one of the industry’s most pressing challenges: how to make lab digitalization work in practice. \nEvery lab is on a different point in its digital journey – whether upgrading legacy systems\, implementing robotics\, or leveraging generative AI to streamline workflows. But the obstacles are universal: harmonizing data\, scaling automation\, and driving adoption across teams. The SmartLab Exchange USA focuses on practical strategies to overcome these hurdles and accelerate transformation. \nWhat to Expect: \n\nInteractive Roundtables: Collaborate with peers to solve common challenges.\nOne-to-One Meetings: Connect with curated solution providers offering tailored answers to your priorities.\nCase Studies & Keynotes: Learn from industry leaders who have successfully implemented digitalization and automation.\n\nUnlike traditional conferences\, the SmartLab Exchange USA offers a highly personalized experience – no crowded exhibition halls\, just focused discussions and strategic networking. This is your opportunity to benchmark your approach\, discover innovative solutions\, and build partnerships that will shape the future of your lab. \nWho Should Attend:\nSenior professionals in R&D\, QA/QC\, IT\, and digital transformation roles who are responsible for driving innovation and operational excellence. \nSpaces are strictly limited. Secure your invitation today and join us in Philadelphia for two days of strategic collaboration and innovation.
URL:http://www.pharmajournalist.com/event/smartlab-exchange-usa-2026/
LOCATION:The Logan Philadelphia\, One Logan Square\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="IQPC Exchange":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260427
DTEND;VALUE=DATE:20260430
DTSTAMP:20260515T020530
CREATED:20260122T134109Z
LAST-MODIFIED:20260122T134334Z
UID:42750-1777248000-1777507199@www.pharmajournalist.com
SUMMARY:PFS & Injectable Drug Devices East Coast
DESCRIPTION:As part of SAE’s leading PFS Series\, the 2026 conference will once again bring together top experts\, industry leaders\, and innovators for a three-days of key insights and networking. The conference will feature a comprehensive pre-conference focus day dedicated to advancements in device design\, followed by a dynamic two-day main conference featuring keynote plenaries\, interactive panel discussions\, and specialized topic streams covering the most pressing industry challenges and breakthrough solutions. \nFor more information\, click here.
URL:http://www.pharmajournalist.com/event/pfs-injectable-drug-devices-east-coast/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="SAE Media Group":MAILTO:neill.howard@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260428
DTEND;VALUE=DATE:20260501
DTSTAMP:20260515T020530
CREATED:20260107T093116Z
LAST-MODIFIED:20260107T093116Z
UID:42669-1777334400-1777593599@www.pharmajournalist.com
SUMMARY:5th ADC Analytical Development Summit
DESCRIPTION:The 5th ADC Analytical Development Summit is the industry’s only dedicated technical forum focused exclusively on solving the analytical challenges unique to antibody–drug conjugate (ADC) development. Designed for analytical\, bioanalytical\, and CMC leaders\, the summit brings together senior experts from across pharma and biotech to advance analytical rigor\, deepen product understanding\, and enable regulatory-ready ADC submissions as modalities grow increasingly complex. \nWhy Attend \n\nAcross three content-packed days\, attendees will gain practical insights to:\nOptimize physicochemical\, potency\, and impurity analytical methods\nDecode ADC heterogeneity and move beyond average DAR measurements\nDevelop biologically relevant bioassays for next-generation ADCs\nNavigate evolving regulatory expectations and strengthen CMC strategies\nStreamline analytical method transfer to QC and CDMOs\n\nWith actionable case studies and real-world lessons\, you’ll stay ahead as bispecifics\, dual payloads\, and novel conjugate formats progress through development pipelines. \nProgram Highlights \n\n22+ expert speakers from leading biopharma and biotech companies\n3 in-depth workshops on advanced ADC analytical strategies\n4+ panel discussions addressing current technical challenges\n12+ hours of structured networking with 80+ senior analytical scientists\n\nFeatured Speakers Include \nFrancis Poulin (Takeda)\, Melvin Flores (Sutro Biopharma)\, John Valliere-Douglas (Pfizer)\, Adrienne Wildt (AbbVie)\, Susan Clardy (Pyxis Oncology)\, and Stacey Cummins-Bitz (Eli Lilly)\, alongside experts from AstraZeneca\, Merck\, BMS\, Johnson & Johnson\, and more. \nDownload the full Event Guide to explore the complete agenda\, workshops\, and speaker faculty: https://ter.li/opm2ur
URL:http://www.pharmajournalist.com/event/5th-adc-analytical-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260428
DTEND;VALUE=DATE:20260501
DTSTAMP:20260515T020530
CREATED:20260122T133529Z
LAST-MODIFIED:20260122T133529Z
UID:42745-1777334400-1777593599@www.pharmajournalist.com
SUMMARY:3rd Peptide-Based Therapeutics Summit 2026
DESCRIPTION:Peptide therapies are rapidly becoming a disruptive modality\, led by Merck’s oral PCSK9 inhibitor and Johnson & Johnson’s IL23R\, with the hope to develop best-in-class drugs with improved chemistry\, formulation and clinical efficacy. \nTo shine a light on the progress of this field\, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and towards life-saving treatments. \nGathering industry leaders including Parabilis Medicines\, Circle Pharma\, Abbvie\, Merck\, Chugai Pharmaceuticals and many more\, this is your premium forum to explore: \n\nNovel computational tools\nOptimize analytical assays\nFormulating cell-specific delivery methods\nDMPK translatability towards clinical success of peptide therapies\n\nWith the likes of Alnylam\, Pfizer\, MIT\, Rapafusyn Pharma\, a stealth start-up and more already booked on to join\, be part of 100+ stakeholders from CEOs to Scientists in disciplines ranging from peptide drug discovery R&D\, medicinal chemistry\, pharmacology and formulation to accelerate this goldilocks modality from concept to commercialization. \nFor more information\, click here.
URL:http://www.pharmajournalist.com/event/3rd-peptide-based-therapeutics-summit-2026/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260428
DTEND;VALUE=DATE:20260430
DTSTAMP:20260515T020530
CREATED:20260220T105915Z
LAST-MODIFIED:20260220T105915Z
UID:42939-1777334400-1777507199@www.pharmajournalist.com
SUMMARY:2nd Neuroscience Innovation Partnering & Licensing Summit
DESCRIPTION:Returning for its second year and building on the momentum of an inaugural edition that drew 100+ senior attendees\, the 2nd Neuroscience Innovation Partnering & Licensing Summit is engineered to facilitate multiple high-impact\, in-person meetings without the distractions of a broader\, less-focused setting. Deliberately timed as an exclusive touchpoint for neuroscience business leaders to reconnect between JPM and BIO through a dedicated one-to-one partnering system\, bespoke matchmaking\, and 100% alignment in research interests. Those attending will receive a significant competitive advantage by hearing insights on aligning data packages with expectations and by nurturing relationships with key contacts in a more exclusive setting. \nWho Attends This Differentiated Business Development Initiative? \nGlobal Pharma: Heads of Business Development\, Search & Evaluation\, and Asset Scouting for Neuroscience – comparing pipelines and enabling technologies to fuel future innovation.\nInnovative Biotech: C-level executives and BD leaders across neurodegeneration\, psychiatry\, neuro-oncology\, and pain – seeking feedback\, validation\, and strategic partnerships with pharma and investors.\nInvestors & Venture Capital: Leaders focused on neuroscience investments with a higher risk appetite – looking for insights into pharma strategy and access to breakthrough opportunities. \nWith Novartis\, Roche\, Biogen\, and AbbVie all signing deals in the last 6 months alone\, now is the time to understand how to align with pharma’s interests\, to capitalize on activity and appetite for best or first-in-class neuroscience assets. \nLearn more: https://ter.li/o2406m
URL:http://www.pharmajournalist.com/event/2nd-neuroscience-innovation-partnering-licensing-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260428
DTEND;VALUE=DATE:20260501
DTSTAMP:20260515T020530
CREATED:20260227T124527Z
LAST-MODIFIED:20260227T124643Z
UID:43045-1777334400-1777593599@www.pharmajournalist.com
SUMMARY:5th GPCRs-Targeted Drug Discovery Summit
DESCRIPTION:The GPCR field is experiencing a renaissance\, driven by renewed investment\, clinical progress\, and next-generation technologies unlocking hundreds of previously untargeted receptors. Furthermore\, we’ve recently seen Takeda and Iambic Therapeutics’ $1.7bn partnership to advance AI-driven small molecule programs\, and Kainova Therapeutics securing $32m CAD to accelerate immuno-oncology and inflammation therapies\, momentum in the GPCR space continues to build. The race is on to validate new GPCRs\, understand dynamic activation mechanisms\, and develop assays that better predict therapeutic efficacy and guide smarter candidate selection. \nReturning as the only industry-led meeting dedicated to GPCR drug discovery\, the 5th GPCR-Targeted Drug Discovery Summit features a jam-packed agenda with: \n\n12+ companies unveiling never seen before data\n12+ C-Level speakers\n9+ presentations on non-small molecule GPCR-targeting drug discovery\n\nThis is the place to learn about the latest targets\, tools\, and therapeutic strategies. Join 80+ GPCR-focused leaders across biopharma to share insights\, build collaborations\, and accelerate next-generation therapeutics from discovery to clinic. \nTo know more visit: https://ter.li/etb3m3
URL:http://www.pharmajournalist.com/event/5th-gpcrs-targeted-drug-discovery-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260505
DTEND;VALUE=DATE:20260508
DTSTAMP:20260515T020530
CREATED:20260223T092942Z
LAST-MODIFIED:20260223T092942Z
UID:42967-1777939200-1778198399@www.pharmajournalist.com
SUMMARY:3rd Measuring Patient Engagement Summit
DESCRIPTION:Patient engagement has shifted from a “nice to have” to a strategic necessity. \nWith regulators expecting defensible evidence\, executives demanding clear ROI\, and funding under tighter scrutiny\, every engagement initiative must show measurable value. Yet many organizations still struggle to demonstrate the true impact of their work. \nThe 3rd Measuring Patient Engagement Summit is the only event dedicated entirely to transforming patient engagement into credible\, quantifiable outcomes. Over three days\, more than 70 senior leaders from pharma\, biotech\, and patient advocacy will come together to share frameworks\, tools\, and real-world approaches that prove how patient insights drive results across development\, access\, and commercialization. \nThrough interactive workshops\, case studies\, and collaborative sessions\, attendees will: \n\nShift from anecdotal reporting to robust\, outcome-based evidence\nBenchmark strategies\, co-develop frameworks\, and measure impact across multi-year programs\nTranslate engagement activities into meaningful influence for regulators\, executives\, and patient communities\nWalk away with peer-tested methods\, practical tools\, and actionable insights to elevate engagement from activity to strategic value\n\nMeasuring activity isn’t enough anymore – demonstrating impact is what moves the industry forward. \nThis summit offers a unique non-competitive environment where you can benchmark your approaches\, collaborate directly with peers\, and gain practical tools to clearly demonstrate the value of patient engagement. For teams facing tighter budgets\, heightened scrutiny\, and rising expectations from stakeholders\, it’s the essential gathering to shift from anecdotal stories to evidence-backed impact\, and to elevate patient‑centric initiatives into strategic\, measurable drivers of organizational success. \nTo know more visit: https://ter.li/8hkio4
URL:http://www.pharmajournalist.com/event/3rd-measuring-patient-engagement-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260512
DTEND;VALUE=DATE:20260515
DTSTAMP:20260515T020530
CREATED:20260217T122509Z
LAST-MODIFIED:20260217T122509Z
UID:42924-1778544000-1778803199@www.pharmajournalist.com
SUMMARY:Investigative & Preclinical Toxicology Summit 2026
DESCRIPTION:Optimize Model Selection\, Accelerate Timelines\, Improve Predictivity of Toxicity \nDates: May 12-14 | Location: Boston\, MA \nWhy Attend \nWith nearly 90% of drug candidates failing in the clinic and one-third of those failures driven by safety preclinical toxicology has reached a critical inflection point. Traditional models are no longer sufficient to predict human risk\, leading to costly late-stage attrition and stalled pipelines. \nThe 2026 summit marks a new era for toxicology. Following the FDA’s 2025 roadmap to reduce reliance on animal testing\, adoption of New Approach Methodologies (NAMs)\, including in vitro\, microphysiological\, and computational models\, is accelerating. CROs and technology developers are releasing innovative platforms\, but challenges remain around predictivity\, validation standards\, and regulatory alignment. \nWhat You’ll Learn \nThis industry-led forum is the only meeting dedicated to benchmarking what truly works in predictive toxicology. Key focus areas include: \n\nEvaluating in vivo\, in vitro\, and in silico strategies\nSharing real IND case studies\nDefining fit-for-purpose model selection across modalities\nAdvancing NAM adoption while ensuring regulatory compliance\n\nWho Should Attend \nIf you are responsible for: \n\nDe-risking first-in-human decisions\nImplementing innovative toxicology strategies\nImproving safety translation from preclinical to clinic\n\n…this summit is your essential forum to separate innovation from hype and build strategies that stand up both clinically and regulatorily. \n📥 Download the Event Guide to explore the full agenda\, speakers\, and registration details: \nOrganiser Name: Hanson Wade\nContact: Nisha Poyser-Reid\ninfo@hansonwade.com\n(+1) 617 455 4188
URL:http://www.pharmajournalist.com/event/investigative-preclinical-toxicology-summit-2026/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson  Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260518
DTEND;VALUE=DATE:20260521
DTSTAMP:20260515T020530
CREATED:20260128T093131Z
LAST-MODIFIED:20260128T093339Z
UID:42798-1779062400-1779321599@www.pharmajournalist.com
SUMMARY:7th TCR-Based Therapies Summit
DESCRIPTION:New assets have entered clinic\, whilst dozens more have been disclosed\, and recent investments such as\, T-Therapeutics’ $91M Series A extension to advance their bispecific towards the clinic and Anocca’s SEK 440M raise\, pinpoint how funding and portfolio decisions have the power to define the trajectory of the TCR field. \nIt is in this context that the 7th TCR-Based Therapies Summit returns to unite fellow biopharma experts in address shared challenges and to bridge the gap between promising clinical data and long-term\, commercially viable TCR-based approaches. \nAcross three focused days\, enter into open discussions\, benchmark with peers\, participate in practical problem-solving and hear new data in presentations led by Immunocore\, Enara Bio\, Regeneron\, Eureka Therapeutics\, T-Cypher Bio\, Zelluna Immunotherapy\, and Aethon Therapeutics. \nJoin us in empowering the community to shape a more durable\, scalable\, and commercially robust future for TCR-based therapies. \nTo know more visit: https://ter.li/uhpzx3
URL:http://www.pharmajournalist.com/event/7th-tcr-based-therapies-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260519
DTEND;VALUE=DATE:20260522
DTSTAMP:20260515T020530
CREATED:20260211T085701Z
LAST-MODIFIED:20260211T085701Z
UID:42865-1779148800-1779407999@www.pharmajournalist.com
SUMMARY:4th Nasal Formulation & Delivery Summit
DESCRIPTION:Biopharma investment into the formulation\, delivery\, and commercialization of intranasal therapies is at an all-time high\, and there has never been such an opportunistic time to pursue nasal delivery. Alongside the market projection for intranasal therapies being forecasted to reach $21.2 billion by 2032\, 2025 breakthroughs included Atzumi being approved for migraine treatment\, and Eli Lilly’s Baqsimi now being applied to severe Hypoglycemia. The clock is ticking for biopharma to master their formulations first time for systemic and CNS targeting\, streamline preclinical and clinical trial success\, and achieve regulatory approval to drive products to market. \nIn response to this recent momentum\, the 4th Nasal Formulation & Delivery Summit is uniting 70+ biopharma professionals across C-levels\, Formulation\, Intranasal\, and roduct Development to overcome drug and device combination challenges\, perfect preclinical translation\, and alter formulations\, to achieve commercial viability for intranasal products. This is the only forum specifically dedicated to industry-focused intranasal formulation\, targeting both systemic and CNS delivery. We will combine a hyper-relevant technical focus with a commercial angle to help see your products through concept to clinic. \nIn uniting large pharma\, expanding mid-sized biotech\, and startup innovators\, you will achieve technical excellence for your formulation and delivery that will future-proof commercialization\, and meet potential partners who will co-develop your intranasal therapies. Adopt groundbreaking insights on pre-clinical and clinical intranasal study data for different delivery methods to obtain practical takeaways that will transform the trajectory of your intranasal success. Join biopharma in igniting a new era of innovation where intranasal delivery holds the power to unparalleled medical benefits. \nTo know more visit: https://ter.li/eqlf0s
URL:http://www.pharmajournalist.com/event/4th-nasal-formulation-delivery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260519
DTEND;VALUE=DATE:20260522
DTSTAMP:20260515T020530
CREATED:20260217T121251Z
LAST-MODIFIED:20260217T124142Z
UID:42916-1779148800-1779407999@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences West
DESCRIPTION:Returning for its 8th year\, LEAP HR: Life Sciences West brings together 100+ senior HR leaders from scaling and stabilizing biotech organizations to navigate volatility and drive measurable business impact. \nAcross three days of high-impact sessions\, including case studies\, benchmarking\, roundtables\, and structured networking\, attendees will gain practical strategies to build lean HR functions\, retain top talent\, and respond to immigration shifts and political change. \nThis is the only forum dedicated to the unique people challenges facing West Coast life sciences organizations. Join us this May to connect\, benchmark\, and lead with confidence in a rapidly evolving market. \nTo know more visit: https://ter.li/caoti5
URL:http://www.pharmajournalist.com/event/leap-hr-life-sciences-west-2026/
LOCATION:Wyndham San Diego Bayside\, 1355 N Harbor Dr\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260610
DTSTAMP:20260515T020530
CREATED:20260211T102827Z
LAST-MODIFIED:20260211T102827Z
UID:42871-1780358400-1781049599@www.pharmajournalist.com
SUMMARY:5th ALS Drug Development Summit
DESCRIPTION:The 5th ALS Drug Development Summit returns to Boston as the ultimate platform honing industry R&D for safer\, more effect and patient-relevant drugs that serve the community\, driving a cure for sporadic and familial ALS. \nWith a brand-new agenda spanning early target exploration through to clinical design\, biomarker strategy\, and regulatory engagement\, attendees will gain comprehensive insights into genetically validated targets\, the evolving biology of TDP 43\, adaptive trial design\, and embedding the patient voice throughout development. \nJoin us for 3 days of unmissable data-driven content\, with 2 tracks spanning discovery to access for the whole team: \nTrack A: Discovery\, Preclinical & Translational – designed for CSOs\, pre-clinical researchers\, discovery scientists\, directors of biology and research\, novel modality scientists\, in viva/in vitro modelling experts and many more\, connect with an intimate group of discovery and preclinical experts for a more discursive session. \nTrack B: Clinical & Regulatory – tailor-made for medical directors\, CMOs\, clinical program leaders\, translational and clinical development heads and clinicians and more; share expertise from diverse clinical challenges and innovation in ALS. \nDesigned for biotech\, pharma\, academia\, and patient advocacy stakeholders\, this unique forum will unite 100+ senior experts and 30+ speakers from companies including AbbVie\, Biogen\, Novartis\, Eli Lilly\, QurAlis\, Prilenia\, Sanofi\, and many more. \nDiscover the full 2026 event guide now to explore all speakers and sessions – https://ter.li/28a6lw
URL:http://www.pharmajournalist.com/event/5th-als-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260605
DTSTAMP:20260515T020530
CREATED:20260224T131937Z
LAST-MODIFIED:20260224T132421Z
UID:42974-1780358400-1780617599@www.pharmajournalist.com
SUMMARY:5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit
DESCRIPTION:The 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit returns to Boston in June 2026 as the premier industry forum dedicated to advancing extrahepatic LNP delivery and next-generation targeted lipid nanoparticle technologies. As the field moves beyond liver-focused delivery\, achieving precise\, selective\, tissue-specific targeting remains one of the most critical challenges in genetic medicine. With growing industry validation – including strategic acquisitions by AbbVie and Bristol Myers Squibb – confidence in targeted LNP platforms is accelerating across biopharma. \nOver 3 content-rich days\, 60+ experts from leading biotech\, pharma\, and academia will share cutting-edge data and practical insights on delivering mRNA\, RNA\, gene-editing\, and cell therapy payloads to extrahepatic tissues\, including immune cells\, muscle\, and adipose tissue. Attendees will explore novel targeting ligands\, active and passive targeting strategies\, innovative lipid chemistries\, and advanced formulation approaches designed to improve biodistribution\, potency\, and safety profiles. \nThe summit will also address critical translational challenges\, including targeted LNP analytics\, scalability\, manufacturability\, and immunogenicity – key hurdles in advancing extrahepatic delivery toward clinical success. Through 13+ data-driven case studies\, 6 interactive workshops\, expert panel discussions\, and dedicated networking sessions\, participants will gain actionable strategies to accelerate development timelines and de-risk clinical progression. \nWith representation from pioneering organizations across the delivery ecosystem\, this meeting provides a unique opportunity to benchmark progress\, forge strategic partnerships\, and overcome bottlenecks limiting cell-specific LNP performance. Whether optimizing formulation\, engineering targeting ligands\, refining preclinical models\, or preparing for clinical translation\, this summit delivers the technical depth required to stay at the forefront of innovation. \nVisit Our Website for More Information. \nhttps://ter.li/rt2poz
URL:http://www.pharmajournalist.com/event/5th-extrahepatic-lipid-based-nanoparticles-delivery-summit/
LOCATION:Hotel AKA Boston Common\, 90 Tremont Street\, Boston\, MA\, 02108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260605
DTSTAMP:20260515T020530
CREATED:20260430T111933Z
LAST-MODIFIED:20260430T111933Z
UID:43436-1780358400-1780617599@www.pharmajournalist.com
SUMMARY:10th R&D Procurement & Sourcing in Pharma Summit
DESCRIPTION:The Future of R&D Procurement Excellence Starts Here! \nThe 10th R&D Procurement & Sourcing in Pharma Summit returns to Boston in June 2026 as the definitive meeting place for procurement\, sourcing and category management leaders across pre‑clinical and clinical R&D. This flagship event is designed to support procurement teams as they transition from transactional buying to strategic\, value‑driven partnership models that accelerate pipeline delivery and protect business continuity. \nBringing together senior R&D procurement leaders from global biopharma\, the summit focuses on strengthening sourcing resilience\, maximising CRO and CMO partnerships\, embedding AI and orchestration tools\, and aligning procurement strategy with scientific and operational ambition across the development lifecycle. \nVisionary Faculty Includes: \n\nNovartis – Strengthening global sourcing resilience amid geopolitical and supply‑chain disruption\nRegeneron Pharmaceuticals – Optimising supplier governance and long‑term strategic partnerships\nVertex Pharmaceuticals – Integrating data\, technology and AI to streamline R&D procurement operations\nTakeda & UCB – Elevating procurement’s influence through early‑stage R&D decision‑making\n\nWhy Attend? \n\nThree days of immersive learning across discovery\, pre‑clinical and clinical procurement tracks\n30+ expert speakers sharing real‑world case studies and practical\, execution‑ready frameworks\nDedicated sessions on AI‑enabled procurement\, supplier relationship management and global sourcing resilience\nExtensive networking opportunities with peers shaping the future of R&D procurement and sourcing\n\nJoin us in Boston to help redefine procurement as a strategic engine for R&D innovation\, delivering speed\, resilience and measurable supplier value across the development pipeline.
URL:http://www.pharmajournalist.com/event/10th-rd-procurement-sourcing-in-pharma-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260608
DTEND;VALUE=DATE:20260611
DTSTAMP:20260515T020530
CREATED:20260320T110845Z
LAST-MODIFIED:20260320T110845Z
UID:43192-1780876800-1781135999@www.pharmajournalist.com
SUMMARY:PFS & Injectable Drug Delivery West Coast
DESCRIPTION:Foster Innovation and Collaboration at the 10th Annual Pre-Filled Syringes and Injectable Drug Devices West Coast Conference! \nJoin us in June 2026 as SAE Media Group’s renowned West Coast event returns\, bringing together biotech pioneers\, pharma leaders\, and device innovators to shape the future of injectable drug delivery. \nThis year’s conference will bring a brand NEW focus day followed by the two-day main conference offering an unparalleled platform to explore cutting-edge advances in combination product technology while fostering collaboration between pharma\, device developers\, and regulators. \nFree to Attend for Pharma and Biotech!* \nWhat You’ll Gain: \n\nActionable insights to strengthen your drug-device portfolio.\nOpportunities to network with key players shaping the injectable drug delivery landscape.\nA future-focused perspective on innovation\, regulation\, and patient-centric care.\nThis must-attend event is your chance to stay ahead in the rapidly evolving injectable drug delivery space. We look forward to welcoming you to the West Coast in June 2026!\nJoin organizations including: AbbVie\, Amgen\, Bristol Myers Squibb\, Ionis Pharmaceuticals\, Protagonist Therapeutics\, Genentech and\, more\n\n*Terms and Conditions apply \nTo learn more and register\, please click here.
URL:http://www.pharmajournalist.com/event/pfs-injectable-drug-delivery-west-coast/
LOCATION:SAN DIEGO MARRIOTT LA JOLLA\, 4240 La Jolla Village Drive\, La Jolla\, San Diego\, CA\, 92037\, United States
ORGANIZER;CN="SAE Media Group":MAILTO:marketingteamlondon@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260609
DTEND;VALUE=DATE:20260612
DTSTAMP:20260515T020530
CREATED:20260224T133550Z
LAST-MODIFIED:20260224T133750Z
UID:42982-1780963200-1781222399@www.pharmajournalist.com
SUMMARY:5th World ADC Summit South Korea
DESCRIPTION:The 5th World ADC Summit South Korea (previously World ADC Asia)\, taking place 9–11 June 2026 in Seoul\, stands as the Asia’s premier meeting dedicated to accelerating next‑generation antibody–drug conjugate (ADC) development. \nAs South Korea rapidly transitions from a biosimilar‑focused market to a global innovator in precision oncology\, ADCs have emerged as a centrepiece of this shift. The summit responds to this momentum by offering a comprehensive\, end‑to‑end forum covering discovery\, preclinical development\, clinical translation\, and CMC innovation. With more than 300 industry experts expected to attend\, the event brings together leading organizations to exchange insights on novel and dual‑payloads\, bispecific ADCs\, and strategies to overcome Topo‑1 resistance and develop best‑in‑class ADCs. \nWhether you are an expert or beginner in the field\, join one of our three content tracks spanning early discovery through manufacturing scale‑up to get up to speed with the latest developments. \nOne Pass\, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade\, this is your opportunity to converge with peers working on targeted protein degradation (TPDs)\, Bispecifics\, and T-cell engagers\, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics. \nTo know more visit: https://ter.li/qznxdj
URL:http://www.pharmajournalist.com/event/5th-world-adc-summit-south-korea/
LOCATION:COEX Magok Lewest\, 143 Magokjungang-ro\, Gangseo-gu\, Seoul\, South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260609
DTEND;VALUE=DATE:20260612
DTSTAMP:20260515T020530
CREATED:20260224T135246Z
LAST-MODIFIED:20260224T135246Z
UID:42990-1780963200-1781222399@www.pharmajournalist.com
SUMMARY:World TPD & Induced Proximity Summit South Korea
DESCRIPTION:The World TPD & Induced Proximity Summit South Korea is the first and only Asian industry event dedicated exclusively to advancing targeted protein degradation (TPD) and induced proximity–based therapeutics. \nAs the global TPD field enters a pivotal era\, with the first PROTAC approval on the horizon and multiple candidates progressing through clinical trials\, South Korea has emerged as a major innovation hub\, fuelled by rapid investment\, strategic partnerships\, and an expanding biotech ecosystem. \nDesigned as an end‑to‑end forum for degraders\, molecular glues\, and degrader antibody conjugates (DACs)\, the summit brings together international opinion leaders and Korean pioneers to address discovery challenges\, translational strategy\, clinical development\, and emerging platform technologies. Deep‑dive sessions explore novel E3 ligases\, AI‑enabled discovery workflows\, proteomics‑driven target identification\, PK/PD optimization\, and case studies showcasing first‑in‑human PROTAC and DAC programs. \nOne Pass\, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade\, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs)\, Bispecifics\, and T-cell engagers\, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics. \nTo know more visit: https://ter.li/tslwfl
URL:http://www.pharmajournalist.com/event/world-tpd-induced-proximity-summit-south-korea/
LOCATION:COEX Magok Lewest\, 143 Magokjungang-ro\, Gangseo-gu\, Seoul\, South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260609
DTEND;VALUE=DATE:20260612
DTSTAMP:20260515T020530
CREATED:20260224T135629Z
LAST-MODIFIED:20260224T135659Z
UID:42993-1780963200-1781222399@www.pharmajournalist.com
SUMMARY:World Bispecific & T-Cell Engager Summit South Korea
DESCRIPTION:The World Bispecific & T‑Cell Engager Summit South Korea is Asia’s first and only industry‑dedicated forum focused on advancing bispecific antibodies and T‑cell engagers (TCEs)\, modalities that are redefining the therapeutic landscape for solid tumors and immune‑driven diseases. Propelled by landmark regulatory approvals such as tarlatamab and ivonescimab\, bispecifics and TCEs have captured global interest for their ability to address previously unmet medical needs. \nThis inaugural summit brings together international experts and regional leaders for deep‑dive sessions on advanced engineering\, co-stimulation strategies\, antibody masking\, conditional activation\, and the design of trispecific and tetraspecific formats. The agenda also explores bispecific ADCs (bsADCs)\, novel target selection\, TCE expansion into autoimmune disease\, translational biology\, and early clinical readouts shaping development priorities. \nAs South Korea positions itself as a rising global powerhouse in targeted therapeutics\, this summit provides a vital forum for advancing first‑in‑class bispecific and TCE‑based therapies with the potential to transform patient outcomes worldwide. \nOne Pass\, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade\, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs)\, Bispecifics\, and T-cell engagers\, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics. \nTo know more visit: https://ter.li/bw174h
URL:http://www.pharmajournalist.com/event/world-bispecific-t-cell-engager-summit-south-korea/
LOCATION:COEX Magok Lewest\, 143 Magokjungang-ro\, Gangseo-gu\, Seoul\, South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260623
DTEND;VALUE=DATE:20260626
DTSTAMP:20260515T020530
CREATED:20260313T132352Z
LAST-MODIFIED:20260313T132352Z
UID:43137-1782172800-1782431999@www.pharmajournalist.com
SUMMARY:8th T-Cell Engager Therapeutics Summit
DESCRIPTION:8th T‑Cell Engager Therapeutics Summit — Your Flagship TCE Meeting \nThe T‑cell engager field is evolving at an unprecedented pace. With multiple clinical approvals now validating the durability and therapeutic relevance of this modality\, and a new wave of next‑generation solid tumor and autoimmune programs rapidly progressing toward the clinic\, TCEs have firmly established themselves as one of the most transformative forces shaping the future of immunotherapy. \nOver the past year\, the landscape has seen a sharp rise in investment\, strategic alliances\, and high‑value partnerships. Landmark collaborations\, including BMS × JanuX Therapeutics\, Candid Therapeutics × WuXi Biologics\, and AbbVie × EvolveImmune\, underscore the growing confidence in immune‑redirecting platforms and the sector’s commitment to accelerating innovation across oncology and autoimmune disease. \nNow moving from Boston to San Diego for 2026\, the 8th T‑Cell Engager Therapeutics Summit remains the industry’s most comprehensive end‑to‑end meeting dedicated exclusively to advancing\, optimizing\, and translating TCEs. This case‑study‑driven forum equips engineering\, discovery\, R&D\, translational\, and clinical development teams with the actionable insights needed to design safer\, more potent\, durable\, and precisely targeted TCEs for solid tumors. The agenda also shines a spotlight on new applications expanding engager biology into autoimmune and inflammatory indications. \nIf accelerating your TCE pipeline is a priority\, this is the meeting you cannot afford to miss. \nWhat’s New in 2026? \nTwo Brand‑New Parallel Tracks\nTailor your learning across two dedicated streams: Discovery & Engineering and Preclinical to Clinical Translation\, enabling deep dives aligned to your role and pipeline stage. \nFresh Clinical Insights in Combination & Precision Immunotherapy\nHear directly from Amgen and Regeneron as they reveal new clinical evidence on chemo‑immunotherapy integration\, co‑stimulation pairings\, and combination‑ready TCE design for deeper\, more durable responses in solid tumors. \nExplore the Full Event Guide \n120+ Industry Attendees\n28+ Expert Speakers\n8+ Hours of Networking\n6 Deep‑Dive Workshops\n1 Modality at the Center\nThe Only Forum Advancing TCEs Across Oncology & Autoimmune Disease \nView the Full Program – See all sessions\, speakers\, and workshops: https://ter.li/fulua0
URL:http://www.pharmajournalist.com/event/8th-t-cell-engager-therapeutics-summit/
LOCATION:The Westin San Diego Bayview\, 400 W Broadway\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260717
DTSTAMP:20260515T020530
CREATED:20260318T153844Z
LAST-MODIFIED:20260318T153844Z
UID:43179-1783987200-1784246399@www.pharmajournalist.com
SUMMARY:4th Obesity & Weight Loss Drug Development Summit
DESCRIPTION:Welcome to the 4th Obesity & Weight Loss Drug Development Summit – the definitive industry-forum dedicated to redefining the standards of metabolic medicine by mastering precision treatment\, preserving functional health\, and navigating the high-stakes transition to next-generation oral and multi-agonist therapies. \nThe obesity therapeutics market has entered a radical transformation. Driven by the unprecedented success of first-generation incretins\, the landscape has reached a critical juncture where “simple weight loss” is no longer enough to win. As we move through 2026\, the industry is under intense pressure to move beyond BMI-centric endpoints and unlock new levels of quality\, targeting the 40% of adults globally who require more than a one-size-fits-all approach. The race is now on to decouple adipose reduction from skeletal muscle atrophy and secure long-term adherence through needle-free\, scalable solutions that promise to transform chronic disease management forever. \nThe 4th Obesity & Weight Loss Drug Development Summit stands as the essential global forum for experts dedicated to accelerating this vital progress. This year\, we are diving deep into the game-changing potential of multi-targeted portfolios\, novel biological pathways and new modalities for a precision medicine approach\, alongside the “Oral-First” revolution. \nHear from the titans of the pharmaceutical industry\, including Novo Nordisk\, Eli Lilly\, and Merck & Co.\, as well as innovative biotechs such as Veru Inc.\, Canary Cure\, and Metsera\, who will share their ground-breaking research on preserving lean mass and preventing post-treatment weight regain. \nDon’t miss this pivotal opportunity to network with 120+ leading experts in the field of advanced obesity therapeutics. Forge crucial collaborations and be part of the solution that will define the 2026 pipeline. \nView the full event guide: https://ter.li/p453jn
URL:http://www.pharmajournalist.com/event/4th-obesity-weight-loss-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260717
DTSTAMP:20260515T020530
CREATED:20260506T130245Z
LAST-MODIFIED:20260506T130245Z
UID:43444-1783987200-1784246399@www.pharmajournalist.com
SUMMARY:2nd Operationalize: Expanded Access Programs Summit West
DESCRIPTION:Across the West Coast\, Expanded Access Programs are entering a new phase. More companies are launching EAPs earlier in development\, supporting patients for longer durations\, and extending access beyond the U.S. into increasingly complex global markets. What was once a reactive\, exception-based activity is now a visible\, repeatable function – bringing heightened expectations around governance\, post-trial access\, sustainability\, and real-world insight generation\, all while ensuring patients are not delayed or disadvantaged. \nThe 2nd Operationalize: Expanded Access Programs Summit West arrives at a critical moment. Purpose-built for West Coast biotech and pharma teams\, this summit brings together senior leaders across Access\, Medical Affairs\, Clinical Operations\, Regulatory\, and Clinical Supply to share how EAPs are being designed\, governed\, and scaled in today’s environment. \nOver three focused days\, the summit tackles the most pressing questions facing EAP teams in 2026 – from navigating evolving U.S. and global regulatory expectations\, to enabling providers and patient advocates\, designing post-trial access strategies\, managing long-duration and rare disease programs\, and applying real-world insights without slowing access. \nThis is not a theoretical discussion. It is a peer-led\, non-competitive forum for teams responsible for delivering access at scale – and for those shaping what Expanded Access must become next. \nTo know more visit: https://ter.li/gk0u1gt1
URL:http://www.pharmajournalist.com/event/2nd-operationalize-expanded-access-programs-summit-west/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point Street\, San Francsico\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260720
DTEND;VALUE=DATE:20260723
DTSTAMP:20260515T020530
CREATED:20260312T132559Z
LAST-MODIFIED:20260312T132559Z
UID:43120-1784505600-1784764799@www.pharmajournalist.com
SUMMARY:6th mRNA-Based Therapeutics Summit
DESCRIPTION:The 6th mRNA‑Based Therapeutics Summit: Accelerating the Next Era of mRNA Medicines \nThe global mRNA landscape is advancing at unprecedented speed\, propelled by scientific breakthroughs and high‑impact biopharma investment. Recent acquisitions – including Eli Lilly and Orna\, BMS and Orbital\, AbbVie and Capstan\, and BioNTech and CureVac – underscore the momentum behind emerging modalities such as in vivo CAR‑T\, gene editing\, and cancer immunotherapies as they move closer to clinical validation and commercial potential. \nAmid this rapid evolution\, the 6th mRNA‑Based Therapeutics Summit returns to Boston this summer as the world’s most influential meeting dedicated to mRNA science and drug development. Bringing together 350+ global leaders from established pharma innovators to trailblazing start‑ups – including Moderna\, Pfizer\, AstraZeneca\, Sanofi\, ParcelBio\, CaVos Therapeutics and Kernal Biologics – as well as regulators from the US FDA\, MHRA and EMA\, the summit serves as the central forum shaping the future of mRNA technology. \nThis year’s revitalized agenda spans three core tracks – Discovery\, Pre‑Clinical & Clinical Development\, and Manufacturing & CMC – while introducing two brand‑new focus days on AI‑Driven mRNA Design and Next‑Generation Delivery Technologies. Across scientific sessions\, case studies\, and collaborative discussions\, attendees will gain exclusive access to emerging data\, regulatory expectations\, and the partnerships driving mRNA toward its next frontier. \nWith 1\,988 mRNA assets currently moving through global pipelines\, the field is scaling faster than ever. The 2026 summit is strategically timed to spotlight major advancements across linear\, circular\, and self‑amplifying RNA platforms; next‑generation vaccine innovation and expanding clinical progress in oncology\, rare diseases\, autoimmune conditions\, and beyond. \nAs the flagship global gathering for mRNA innovators\, this summit remains the definitive place to connect with key decision makers\, forge new strategic partnerships\, and refine development and delivery strategies. From protein replacement to cell and gene therapeutics and transformative delivery technologies\, the 6th mRNA‑Based Therapeutics Summit equips teams with the insights\, networks\, and momentum needed to accelerate candidates to clinical and commercial success and ultimately deliver life‑changing medicines to patients worldwide. \nTo know more visit: https://ter.li/axdw1v
URL:http://www.pharmajournalist.com/event/6th-mrna-based-therapeutics-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260720
DTEND;VALUE=DATE:20260723
DTSTAMP:20260515T020530
CREATED:20260320T111737Z
LAST-MODIFIED:20260320T111820Z
UID:43198-1784505600-1784764799@www.pharmajournalist.com
SUMMARY:5th Liquid Biopsy for Precision Oncology Summit East Coast
DESCRIPTION:The 5th Liquid Biopsy for Precision Oncology Summit East Coast returns as your laser-focused forum dedicated to the acceleration\, progression and real-world adoption of liquid biopsies. Expect to unite with 100+ biopharma professionals from Pfizer\, AbbVie\, Takeda\, AstraZeneca\, GSK and more to redefine your clinical trial strategies and advance oncology drug development forward. \nBoasting a speaker faculty consisting of over 70% large pharma\, alongside leading biotech and consortia\, this year’s meeting will not just be a forum to listen. It will be where the practical conversations shaping future decisions on patient stratification\, MRD implementation and dose optimization happen in real time. \nTake a sneak peek at what lies ahead this year: \n\nIdentify why pharma must be the ones to lead early detection in a session led by the Global Senior Director\, Early Detection at AstraZeneca\nUtilize ctDNA dynamics as an early measure of treatment effect to go beyond RECIST in a presentation hosted by the Chief Executive Officer at Marengo Therapeutics\nHear how senior pharma leaders at AbbVie\, Takeda\, AstraZeneca and GSK are rewriting drug development decisions with novel liquid biopsies\nDiscover how you can accelerate clinical development with ctDNA clearance and multi-omic profiling in an exclusive discussion moderated by the Director\, Next-Generation Diagnostics at Novartis\n\nWhether you’re evaluating the right liquid biopsy platform for your specific trial\, looking to gain peer-insight into ctDNA and multi-omic profiling\, or aligning internal strategies with evolving regulatory expectations\, this meeting will provide you with the clarity\, and confidence to take that next step. \nTogether let’s harness the power of liquid biopsies to drive smarter\, better and more precise clinical decisions for patients in need. \nTo learn more and register\, please click here.
URL:http://www.pharmajournalist.com/event/5th-liquid-biopsy-for-precision-oncology-summit-east-coast/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR